Patents by Inventor Ian STEFANUTI

Ian STEFANUTI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl-cyanoguanidine compounds
    Patent number: 10023539
    Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumor disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: July 17, 2018
    Assignee: Bayer Pharma Aktiengesellschaft
    Inventors: Jeffrey Stuart Mowat, Timo Stellfeld, Carlo Stresemann, Roman Hillig, Silke Köhr, Detlef Stöckigt, Jörg Weiske, Thomas Brumby, Naomi Barak, Clara Christ, Antonius Ter Laak, Volker Badock, Rosemary Helen Crampton, Ian Stefanuti
  • NOVEL ARYL-CYANOGUANIDINE COMPOUNDS
    Publication number: 20180099937
    Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (I), wherein R1, R2, R3, R4 and R5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.
    Type: Application
    Filed: April 14, 2016
    Publication date: April 12, 2018
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Timo STELLFELD, Jeffrey Stuart MOWAT, Carlo STRESEMANN, Roman HILLIG, Silke KÖHR, Detlef STÖCKIGT, Jörg WEISKE, Ingo HARTUNG, Naomi BARAK, Clara CHRIST, Antonius TER LAAK, Volker BADOCK, Rosemary Helen CRAMPTON, Ian STEFANUTI
  • NOVEL ARYL-CYANOGUANIDINE COMPOUNDS
    Publication number: 20170342034
    Abstract: The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2, R3, R4, R5, X and r have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyper-proliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.
    Type: Application
    Filed: December 8, 2015
    Publication date: November 30, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Jeffrey Stuart MOWAT, Timo STELLFELD, Carlo STRESEMANN, Roman HILLIG, Silke KÖHR, Detlef STÖCKIGT, Jörg WEISKE, Thomas BRUMBY, Naomi BARACK, Clara CHRIST, Antonius TER LAAK, Volker BADOCK, Rosemary Helen CRAMPTON, Ian STEFANUTI
  • BET-PROTEIN INHIBITING 3,4-DIHYDROPYRIDO[2,3-B]PYRAZINONES WITH META-SUBSTITUTED AROMATIC AMINO- OR ETHER GROUPS
    Publication number: 20170121322
    Abstract: The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory 3,4-dihydropyrido[2,3-b]pyrazinones with a meta-substituted aromatic amino or ether group of the general formula (I) in which A, X, Y, R1, R2, R3, R4, R5, R6 and n are each as defined in the description, to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof in the case of hyperproliferative disorders, especially in the case of tumour disorders. Furthermore, this invention relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
    Type: Application
    Filed: June 15, 2015
    Publication date: May 4, 2017
    Applicant: Bayer Pharma Aktiengesellschaft
    Inventors: Norbert SCHMEES, Bernard HAENDLER, Detlef STÖCKIGT, Richard Alexander BISSELL, Richard Alexander BOUGLAS, Ian STEFANUTI, Stephan SIEGEL